SOURCE: Radient Pharmaceuticals Corporation

Radient Pharmaceuticals Corporation

July 21, 2011 12:17 ET

Radient Pharmaceuticals Participates in American Association of Clinical Chemists Annual Meeting and Clinical Lab Expo

TUSTIN, CA--(Marketwire - Jul 21, 2011) - Radient Pharmaceuticals Corporation "the Company" or "Radient" (OTCQX: RXPC) (PINKSHEETS: RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced it will participate in the American Association of Clinical Chemists (AACC) Annual Meeting and Clinical Lab Expo in Atlanta, Georgia from July 24 through 28. The company's sales and marketing executives will be representing Radient and its FDA-cleared Onko-Sure® cancer test at booth #3719. AACC's annual meeting, the world's largest lab conference, attracts about 17,000-19,000 registrants from more than 100 countries.

"We look forward to AACC next week where, not only will Onko-Sure® be displayed, our sales and marketing executives will engage in meaningful dialog with medical device and diagnostics distributors and labs from around world as well as the US," stated Radient's CEO and Chairman, Mr. Douglas MacLellan. "There are several international territories in which we are looking to make deeper inroads. In the US we are looking to have our test offered by a growing number of labs. We have already opened a dialog with several companies attending the conference and we expect further progress towards solidifying those relationships."

AACC is an international scientific and medical society of clinical laboratory professionals, physicians, research scientists and other individuals involved with clinical chemistry and related disciplines. Founded in 1948, the society has 10,000 members and is headquartered in Washington, DC.

For additional information on Radient Pharmaceuticals Corporation and its products visit: www.radient-pharma.com or e-mail info@radient-pharma.com. For Investor Relations contact Dilek Mir at: ir@radient-pharma.com or 714-881-0244.

The following table is intended to provide the latest information on Radient's business metrics.

RPC's Business Metrics
Cash on hand: $1.35 million*

*Approximate amount as of July 19, 2011
Shares Outstanding: 181 million*

*Approximate number as of July 19, 2011 and there are 200 million shares fully authorized.
Outstanding Warrants & Options: 111.1 million*

*Approximate number as of July 19, 2011

About Radient Pharmaceuticals:

Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit www.radient-pharma.com.

Forward-Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.